Imre Noth, MD, the chief of UVA Health’s Division of Pulmonary and Critical Care Medicine, says the study of idiopathic pulmonary fibrosis will still benefit efforts to battle the lung-scarring disease.

Imre Noth, MD, the chief of UVA Health’s Division of Pulmonary and Critical Care Medicine, says the study of idiopathic pulmonary fibrosis will still benefit efforts to battle the lung-scarring disease.